Dose tolerability of chronically inhaled voriconazole solution in rodents

International Journal of Pharmaceutics

Volumn 379, Issue 1-2, 2009, Pages 25-31

  Tolman, Justin A ^a   Nelson, Nicole A ^a   Bosselmann, Stephanie ^a   Peters, Jay I ^b   Coalson, Jacqueline J ^c   Wiederhold, Nathan P ^a,b   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Animal; Blood; Captisol ; Cyclodextrin; Inhaled; Lung; Pathology; Rat; Rodent; Tissue; Tolerability; Toxicity; Voriconazole

Indexed keywords

BETA CYCLODEXTRIN SULFOBUTYL ETHER; UNCLASSIFIED DRUG; VFEND IV; VORICONAZOLE;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FEMALE; HEMATOCRIT; HISTOPATHOLOGY; INFLAMMATION; LONG TERM EXPOSURE; LOW DRUG DOSE; LUNG ALVEOLUS MACROPHAGE; LUNG PARENCHYMA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, INHALATION; ANIMALS; ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; INVASIVE PULMONARY ASPERGILLOSIS; LUNG; MACROPHAGES, ALVEOLAR; MALE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; TRIAZOLES;

EID: 68649109291     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.06.003     Document Type: Article

References (66)

1. Alvarez C.A., Wiederhold N.P., Mcconville J.T., Peters J.I., Najvar L.K., Graybill J.R., Coalson J.J., Talbert R.L., Burgess D.S., Bocanegra R., Johnston K.P., and Williams III R.O. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J. Infect. 55 (2007) 68-74
2. Beyer J., Schwartz S., Barzen G., Risse G., Dullenkopf K., Weyer C., and Siegert W. Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis. Infection 22 (1994) 143-148
3. Brazil T.J., Dagleish M.P., Mcgorum B.C., Dixon P.M., Haslett C., and Chilvers E.R. Kinetics of pulmonary neutrophil recruitment and clearance in a natural and spontaneously resolving model of airway inflammation. Clin. Exp. Allergy 35 (2005) 854-865
4. Brueggemann R.J.M., Donnelly J.P., Aarnoutse R.E., Warris A., Blijlevens N.M.A., Mouton J.W., Verweij P.E., and Burger D.M. Therapeutic drug monitoring of voriconazole. Therap. Drug Monitor. 30 (2008) 403-411
5. Capitano B., Potoski B.A., Husain S., Zhang S., Paterson D.L., Studer S.M., Mccurry K.R., and Venkataramanan R. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob. Agents Chemother. 50 (2006) 1878-1880
6. Carrier R.L., Miller L.A., and Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J. Controlled Release 123 (2007) 78-99
7. Cimolai N., Taylor G.P., Mah D., and Morrison B.J. Definition and application of a histopathological scoring scheme for an animal model of acute Mycoplasma pneumoniae pulmonary infection. Microbiol. Immunol. 36 (1992) 465-478
8. Cohen B.E. Amphotericin B toxicity and lethality. Int. J. Pharm. 162 (1998) 95-106
9. Cornet M., Afleury L., Maslo C., Bernard J.F., and Brucker G. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J. Hosp. Infect. 51 (2002) 288-296
10. Davis J.L., Salmon J.H., and Papich M.G. Pharmacokinetics of voriconazole after oral and intravenous administration to horses. Am. J. Vet. Res. 67 (2006) 1070-1075
11. Denning D.W. Invasive aspergillosis. Clin. Infect. Dis. 26 (1998) 781-803 quiz 804-5
12. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., Haas A., Rubnke M., and Lode H. Efficacy and safety of voriconazole in the treatment of acute invasive Aspergillosis. Clin. Infect. Dis. 34 (2002) 563-571
13. Dixon S., Mckeen E., Tabberer M., and Paisley S. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. Pharmacoeconomics 22 (2004) 421-433
14. Dubois J., Bartter T., Gryn J., and Pratter M.R. The physiologic effects of inhaled amphotericin B. Chest 108 (1995) 750-753
15. Dummer J.S., Lazariashvilli N., Barnes J., Ninan M., and Milstone Aaron P. A survey of anti-fungal management in lung transplantation. J. Heart Lung Transplant. 23 (2004) 1376-1381
16. Erjavec Z., Woolthuis G.M.H., De Vries-Hospers H.G., Sluiter W.J., Daenen S.M.G.J., De Pauw B., and Halie M.R. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in hematological patients. Eur. J. Clin. Microbiol. 16 (1997) 364-368
17. Evrard B., Bertholet P., Gueders M., Flament M.P., Piel G., Delattre L., Gayot A., Leterme P., Foidart J.M., and Cataldo D. Cyclodextrins as a potential carrier in drug nebulization. J. Controlled Release 96 (2004) 403-410
18. Fels A.O., and Cohn Z.A. The alveolar macrophage. J. Appl. Physiol. 60 (1986) 353-369
19. Gabardi S., Kubiak D.W., Chandraker A.K., and Tullius S.G. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transpl. Int. 20 (2007) 993-1015
20. Gavalda J., Martin M.-T., Lopez P., Gomis X., Ramirez J.-L., Rodriguez D., Len O., Puigfel Y., Ruiz I., and Pahissa A. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob. Agents Chemother. 49 (2005) 3028-3030
21. Gelman S. Role of oxygen availability to the liver in anesthesia-induced hepatotoxicity. Mol. Cell. Mech. Anesth. (1986) 427-431
22. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.-W., Kern W.V., Marr K.A., Ribaud P., Lortholary O., Sylvester R., Rubin R.H., Wingard J.R., Stark P., Durand C., Caillot D., Thiel E., Chandrasekar P.H., Hodges M.R., Schlamm H.T., Troke P.F., De Pauw B., Allen R., Aoun M., Aul C., Bjorkholm M., Blanchard K.L., Boogaerts M., Bouza E., Bow E.J., Brodt H.R., Brown J., Buchheidt D., Cahn J.Y., Calmaggi A., Cisneros J.M., Cordonnier C., Daly J., Da Cunha C.A., De Bock R., Del Favero A., Diaz Mediavilla J., Dignani M.C., Doyen C., Dummer J.S., Dupont B., Egyed M., Engelhard D., Faetkenheuer G., Feld R., Fiere D., Fioritoni G., Garber G., Gasztonyi Z., Godder K., Graham D., Gratwohl A., Greenberg R., High K., Jacobs F., Kremery V., Kumar P., Langer W., Laverdiere M., Ljungman P., Lode H., Louie A., Maki D., Marie J.P., Marriott D.J.E., Mckinsey D.S., Mertelsmann R., Nair M.K., Milpied N., Nagler A., Niederwieser D., Pagano L., Pappas P., Perfect J., Pottage J., Raina V., Reinhardt J., Richardson S., Rickman L., Ruhnke M., Salit I., Scheld W.M., Schuler S., Schuster M., Schwerdtfeger R., Shafran S.D., Simmons B., Slavin M., Sokol-Anderson M., Tebas P., Tsoukas C., Ullmann A., Van Burik J., Van't Wout J.W., Vinaya Kumar E.C., et al. Voriconazole versus amphotericin B for primary therapy on invasive aspergillosis. N. Engl. J. Med. 347 (2002) 408-415
23. Hoeben B.J., Burgess D.S., Mcconville J.T., Najvar L.K., Talbert R.L., Peters J.I., Wiederhold N.P., Frei B.L., Graybill J.R., Bocanegra R., Overhoff K.A., Sinswat P., Johnston K.P., and Williams III R.O. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 50 (2006) 1552-1554
24. Hursh D., Gelman S., and Bradley Jr. E.L. Hepatic oxygen supply during halothane or isoflurane anesthesia in guinea pigs. Anesthesiology 67 (1987) 701-706
25. Husain S., Paterson D.L., Studer S., Pilewski J., Crespo M., Zaldonis D., Shutt K., Pakstis D.L., Zeevi A., Johnson B., Kwak E.J., and Mccurry K.R. Voriconazole prophylaxis in lung transplant recipients. Am. J. Transplant. 6 (2007) 3008-3016
26. Irie T., and Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86 (1997) 147-162
27. Lattermann R., Schricker T., Wachter U., Georgieff M., and Goertz A. Understanding the mechanisms by which isoflurane modifies the hyperglycemic response to surgery. Anesth. Analg. 93 (2001) 121-127
28. Lin S.J., Schranz J., and Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32 (2001) 358-366
29. Lowry C.M., Marty F.M., Vargas S.O., Lee J.T., Fiumara K., Deykin A., and Baden L.R. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl. Infect. Dis. 9 (2007) 121-125
30. Lutsar I., Roffey S., and Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin. Infect. Dis. 37 (2003) 728-732
31. Marra F., Partovi N., Wasan K.M., Kwong E.H., Ensom M.H.H., Cassidy S.M., Fradet G., and Levy R.D. Amphotericin B disposition after aerosol inhalation in lung transplant recipients. Ann. Pharmacother. 36 (2002) 46-51
32. Maschmeyer G. The changing epidemiology of invasive fungal infections: new threats. Int. J. Antimicrobial Agents 27 (2006) 3-6
33. Maschmeyer G., Haas A., and Cornely O.A. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 67 (2007) 1567-1601
34. Mcconville J.T., Overhoff K.A., Sinswat P., Vaughn J.M., Frei B.L., Burgess D.S., Talbert R.L., Peters J.I., Johnston K.P., and Williams III R.O. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm. Res. 23 (2006) 901-911
35. Miyake K., Arima H., Irie T., Hirayama F., and Uekama K. Enhanced absorption of cyclosporin A by complexation with dimethyl-beta -cyclodextrin in bile duct-cannulated and -noncannulated rats. Biol. Pharm. Bull. 22 (1999) 66-72
36. Mohammad R.A., and Klein K.C. Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections. Ann. Pharmacother. 40 (2006) 2148-2154
37. Monforte V., Roman A., Gavalda J., Lopez R., Pou L., Simo M., Aguade S., Soriano B., Bravo C., and Morell F. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung transplanted patients. Transplantation 75 (2003) 1571-1574
38. Nakate T., Yoshida H., Ohike A., Tokunaga Y., Ibuki R., and Kawashima Y. Improvement of pulmonary absorption of cyclopeptide FK224 in rats by co-formulating with beta -cyclodextrin. Eur. J. Pharm. Biopharm. 55 (2003) 147-154
39. Pascual A., Calandra T., Bolay S., Buclin T., Bille J., and Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycosis improves efficacy and safety outcomes. Clin. Infect. Dis. 46 (2008) 201-211
40. Pascual A., Nieth V., Calandra T., Bille J., Bolay S., Decosterd L.A., Buclin T., Majcherczyk P.A., Sanglard D., and Marchetti O. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob. Agents Chemother. 51 (2007) 137-143
41. Patterson T.F. Advances and challenges in management of invasive mycoses. Lancet 366 (2005) 1013-1025
42. Pinkerton K.E., Mercer R.R., Plopper C.G., and Crapo J.D. Distribution of injury and microdosimetry of ozone in the ventilatory unit of the rat. J. Appl. Physiol.y 73 (1992) 817-824
43. Playford E.G., Webster A.C., Sorrell T.C., and Craig J.C. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J. Antimicrob. Chemother. 57 (2006) 628-638
44. Playford E.G., Webster A.C., Sorrell T.C., and Craig J.C. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur. J. Clin. Microbiol. 25 (2006) 549-561
45. Purvis T., Vaughn Jason M., Rogers True L., Chen X., Overhoff Kirk A., Sinswat P., Hu J., Mcconville Jason T., Johnston Keith P., and Williams Robert III O. Cryogenic liquids, nanoparticles, and microencapsulation. Int. J. Pharm. 324 (2006) 43-50
46. Roerig Division of Pfizer Inc. Vfend Prescribing Information (2006), Pfizer Inc., New York, NY
47. Roffey S.J., Cole S., Comby P., Gibson D., Jezequel S.G., Nedderman A.N.R., Smith D.A., Walker D.K., and Wood N. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab. Dispos. 31 (2003) 731-741
48. Ruijgrok E.J., Vulto A.G., and Van Etten E.W.M. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J. Antimicrob. Chemother. 48 (2001) 89-95
49. Saha J.K., Xia J., Grondin J.M., Engle S.K., and Jakubowski J.A. Acute hyperglycemia induced by ketamine/xylazine anesthesia in rats: Mechanisms and implications for preclinical models. Exp. Biol. Med. 230 (2005) 777-784
50. Schlage W.K., Bulles H., Friedrichs D., Kuhn M., Teredesai A., and Terpstra P.M. Cytokeratin expression patterns in the rat respiratory tract as markers of epithelial differentiation in inhalation toxicology. II. Changes in cytokeratin expression patterns following 8-day exposure to room-aged cigarette sidestream smoke. Toxicol. Pathol. 26 (1998) 344-360
51. Schmitt H.J., Bernard E.M., Haeuser M., and Armstrong D. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob. Agents Chemother. 32 (1988) 1676-1679
52. Schwartz S., Behre G., Heinemann V., Wandt H., Schilling E., Arning M., Trittin A., Kern W.V., Boenisch O., Bosse D., Lenz K., Ludwig W.D., Hiddemann W., Siegert W., and Beyer J. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 93 (1999) 3654-3661
53. Scott L.J., Simpson D., Blot S.I., Chandrasekar P.H., Groll A.H., Hobson R.P., Kan V.L., Keady S., and Walsh T.J. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 67 (2007) 269-298
54. Stella V.J., and He Q. Cyclodextrins. Toxicol. Pathol. 36 (2008) 30-42
55. Sugar A.M., and Liu X.P. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med. Mycol. 38 (2000) 209-212
56. Theuretzbacher U., Ihle F., and Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin. Pharmacokin. 45 (2006) 649-663
57. Tolman J.A., Nelson N.A., Son Y.J., Bosselmann S., Wiederhold N.P., Peters J.I., Mcconville J.T., and Williams R.O. Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. Eur. J. Pharm. Biopharm. 72 (2009) 199-205
58. Tolman J.A., Wiederhold N.P., Mcconville J.T., Najvar L.K., Bocanegra R., Peters J.I., Coalson J.J., Graybill J.R., Patterson T.F., and Williams III R.O. Inhaled Voriconazole for the Prevention of Invasive Pulmonary Aspergillosis. Antimicrob. Agents Chemother. 53 (2009) 2613-2615
59. Vaughn J.M., Mcconville J.T., Burgess D., Peters J.I., Johnston K.P., Talbert R.L., and Williams III R.O. Single dose and multiple dose studies of itraconazole nanoparticles. Eur. J. Pharm. Biopharm. 63 (2006) 95-102
60. Vaughn J.M., Wiederhold N.P., Mcconville J.T., Coalson J.J., Talbert R.L., Burgess D.S., Johnston K.P., Williams R.O., and Peters J.I. Murine airway histology and intracellular uptake of inhaled amorphous itraconazole. Int. J. Pharm. 338 (2007) 219-224
61. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., Morrison V.A., Segal B.H., Steinbach W.J., Stevens D.A., Van Burik J.-A., Wingard J.R., and Patterson T.F. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46 (2008) 327-360
62. Walsh T.J., Karlsson M.O., Driscoll T., Arguedas A.G., Adamson P., Saez-Llorens X., Vora A.J., Arrieta A.C., Blumer J., Lutsar I., Milligan P., and Wood N. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48 (2004) 2166-2172
63. Yang W., Peters J.I., and Williams III R.O. Inhaled nanoparticles. A current review. Int. J. Pharm. 356 (2008) 239-247
64. Yang W., Tam J., Miller D.A., Zhou J., Mcconville J.T., Johnston K.P., and Williams R.O. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int. J. Pharm. 361 (2008) 177-188
65. Yang W., Wiederhold N.P., and Williams III R.O. Drug delivery strategies for improved azole antifungal action. Expert Opin. Drug Delivery 5 (2008) 1199-1216
66. Zardooz H., Zahedi Asl S., Gharib Naseri M.K., and Hedayati M. Effect of chronic restraint stress on carbohydrate metabolism in rat. Physiol. Behav. 89 (2006) 373-378